CGRP Medications for Post-Traumatic Migraine: A Complete Guide for Personal Injury Attorneys and Patients

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | September 19, 2024 | 9 min read

CGRP medications represent the most significant advance in migraine treatment in decades — and they are increasingly prescribed for personal injury patients who develop post-traumatic migraine after accidents. This guide explains how CGRP drugs work, which medications fall into this class, and why they matter in personal injury cases.

CGRP Medications for Post-Traumatic Migraine: A Complete Guide

Calcitonin gene-related peptide — CGRP — has transformed the treatment of migraine over the past several years, and its relevance to personal injury medicine is substantial. Trauma is one of the most well-documented triggers for new-onset or worsening migraine, and the medications that target the CGRP pathway are now first-line therapy for patients who develop post-traumatic headache following car accidents, falls, and other injury events.

For personal injury attorneys and patients, understanding CGRP medications is increasingly important. These are brand-name-only drugs prescribed by neurologists and headache specialists, they generate detailed prescription records, and their use directly documents the severity and duration of post-traumatic neurological injury.

[!KEY] CGRP medications — including Qulipta, Nurtec ODT, Aimovig, and Vyepti — are prescribed by neurologists for post-traumatic migraine. Every monthly refill creates an objective, specialist-level record of ongoing neurological injury management.

[!SOURCE] FDA CGRP Drug Approvals — FDA-approved CGRP antagonists for migraine prevention and treatment.

What Is CGRP and Why Does It Matter After an Injury?

CGRP is a neuropeptide found throughout the nervous system that plays a critical role in migraine pathophysiology. During a migraine attack, CGRP levels rise sharply in the blood and cerebrospinal fluid, causing vasodilation of cranial blood vessels and amplifying pain signals through the trigeminal nerve system.

Trauma activates this same pathway. When the head, neck, or spine is injured — as in a rear-end collision, a fall, or a struck-pedestrian accident — the physical insult triggers neurogenic inflammation that releases CGRP. In patients with underlying migraine susceptibility, this release can initiate or dramatically worsen migraine. In patients with no prior migraine history, repeated trauma-induced CGRP release can sensitize the trigeminal system, creating de novo post-traumatic migraine.

This is why post-traumatic migraine is a recognized clinical entity, distinct from simple headache, and why CGRP-targeted therapy is medically appropriate for many personal injury patients.

Two Categories of CGRP Medications

CGRP medications fall into two broad categories based on their mechanism and route of administration.

Category 1: Gepants (Oral CGRP Antagonists)

Gepants are small-molecule drugs taken by mouth that block the CGRP receptor, preventing CGRP from triggering its downstream effects. They are taken either as needed for acute attacks or daily for prevention.

Atogepant (Qulipta) — Oral tablet taken once daily for migraine prevention. Available in 10mg, 30mg, and 60mg doses. FDA-approved for both episodic and chronic migraine. Provides sustained daily protection, which is particularly appropriate for PI patients with frequent post-traumatic headaches.

Rimegepant (Nurtec ODT) — Orally dissolving tablet with a unique dual indication: it can be taken as needed for acute migraine attacks (75mg as needed, up to every 48 hours) AND taken every other day for prevention. This makes it unusually versatile for PI patients who need both acute and preventive coverage.

Ubrogepant (Ubrelvy) — Oral tablet for acute migraine treatment, available in 50mg and 100mg doses. Taken at the onset of a migraine attack, with a second dose if needed two hours later. Appropriate for patients with moderate-to-severe acute episodes.

Zavegepant (Zavzpret) — Nasal spray for acute migraine, 10mg per dose. Onset of action is rapid. Well-suited for patients with nausea who struggle to swallow tablets during attacks.

Category 2: CGRP Monoclonal Antibodies (Injectable)

CGRP monoclonal antibodies take a different approach: rather than blocking the CGRP receptor in real time, they are large proteins that bind to either CGRP itself or its receptor and neutralize it over an extended period. These are administered by injection or infusion, typically monthly or quarterly.

Erenumab (Aimovig) — Monthly subcutaneous injection, 70mg or 140mg. Self-administered with an autoinjector. The first CGRP monoclonal antibody approved by the FDA (2018). Blocks the CGRP receptor itself rather than the CGRP ligand.

Galcanezumab (Emgality) — Monthly subcutaneous injection, 120mg. Self-administered. Also FDA-approved for cluster headache prevention, which can be triggered by head trauma.

Fremanezumab (Ajovy) — Available as monthly (225mg) or quarterly (675mg) subcutaneous injection. Quarterly dosing is an important option for PI patients — three months of continuous migraine prevention from a single injection creates a clear, defensible treatment record.

Eptinezumab (Vyepti) — Administered as an intravenous infusion every three months. Unlike the self-injected options, Vyepti is given in a clinical setting, making it the highest per-administration cost option in this class and generating infusion records alongside prescription records.

How CGRP Medications Are Used Together

A neurologist treating post-traumatic migraine typically combines medications from both categories. The logic is straightforward: a preventive medication reduces the baseline frequency and severity of migraines, while an acute rescue medication addresses breakthrough attacks that occur despite prevention.

A common combination is a daily oral gepant like Qulipta for prevention plus Ubrelvy or Zavzpret for acute rescue. Alternatively, a monthly CGRP antibody injection handles prevention while Nurtec ODT provides both preventive benefit (when taken every other day) and acute rescue when needed. These combinations are not duplicative — they address different phases and dimensions of the migraine condition.

[!KEY] A Qulipta daily preventive plus Ubrelvy acute rescue combination in a PI pharmacy record documents both that the patient's post-traumatic migraine frequency justified daily prevention and that breakthrough episodes still occurred despite that prevention — together these establish a neurological burden of injury that is difficult for the defense to minimize.

What Attorneys Should Know

CGRP Prescriptions Signal Neurological Involvement

When a treating neurologist prescribes CGRP medication after a personal injury, it signals a formal clinical assessment that the patient has developed post-traumatic migraine severe enough to warrant specialty pharmacotherapy. This is not a medication prescribed for mild headaches. The clinical threshold for initiating CGRP therapy — typically four or more migraine days per month for preventive therapy — reflects genuine disability.

Monthly Prescriptions Create a Timeline of Sustained Injury

CGRP preventive medications are taken continuously over months. Monthly injections like Aimovig or Emgality, quarterly infusions like Vyepti, or daily tablets like Qulipta each generate prescription and administration records that document the ongoing nature of the post-traumatic neurological condition. A client on CGRP therapy for twelve months has twelve months of documented, medication-supported neurological injury.

The Brand-Name Status Is Clinically Relevant

All CGRP medications are currently brand-name only. There are no generic alternatives. This reflects the novelty of the drug class and the patent protection on these targeted biologics. The brand-name status is not a preference — it is the only available option — which directly supports the pharmacy lien value.

These Are Prescribed by Neurologists

CGRP medications require neurologist or headache specialist prescribers, which adds specialist documentation to the treatment record. An attorney can request not only pharmacy lien records but also the neurological evaluation notes that justified CGRP therapy — a powerful addition to the demand package.

The Connection Between Trauma, CGRP, and Case Value

Post-traumatic migraine documented by CGRP therapy is among the strongest pharmacological evidence of neurological injury in a personal injury case. The specificity of these medications — they target one molecular pathway implicated in migraine — means that prescribing them reflects a precise clinical diagnosis, not a general symptomatic prescription.

[!KEY] Because all CGRP medications are currently brand-name only with no generic alternatives, a defense argument that lien pharmacy costs are "inflated" fails for this drug class — the lien charge reflects the actual market cost of the only available therapy, and the prescribing neurologist's documentation supports medical necessity for every monthly fill.

For patients, CGRP medications represent modern, effective treatment that many had not accessed before their injury. For attorneys, CGRP prescriptions create a documented trail of neurological impairment that is difficult to minimize in settlement negotiations or at trial.

If your client has been prescribed CGRP medications following a personal injury and needs help with medication access or lien-based pharmacy coverage, LienScripts provides pharmacy services specifically designed for personal injury cases.

Related Resources

• Qulipta (Atogepant): Preventive Migraine Treatment After a Personal Injury
• Nurtec ODT (Rimegepant): Dual Acute and Preventive Migraine Treatment
• Migraine and Headache Medications After TBI or Whiplash
• Why PI Patients Often Need Multiple Medications
• Pharmacy Services for Personal Injury Clients: How It Works
• What Are Medication Liens?